In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...

High Yield Municipal Fund A Shares (without sales charge*) posted a return of 0.77% in Q3 2025. It underperformed the S&P ...

Day One Biopharmaceuticals, Inc. is rated a Strong Buy with robust product growth, pipeline expansion & strategic acquisition ...

Katapult Holdings, Inc. (NASDAQ: KPLT) Q3 2025 Earnings Call Transcript November 12, 2025 Katapult Holdings, Inc. beats ...

Coronal mass ejections, or CMEs, are large clouds of ionized gas called plasma and magnetic fields that erupt from the sun’s outer atmosphere. When these outbursts are directed at Earth, they can ...

Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...

Q3 2025 Earnings Call Transcript November 13, 2025 Operator: Greetings, and welcome to the HeartBeam Third Quarter 2025 ...

(OTCQX: DYNR) (“DynaResource” or the “Company”) is pleased to report results for the three months ending September 30, 2025 (“Q3 2025”) at the San Jose de Gracia (“SJG”) Mine located in the center of ...

Diamond drilling at Majorodam, Suriname confirms the presence of a mineralized zone at least 800 m long at Heuvel Main in ...

Infrastructure adjusted EBITDA in the third quarter of 2025 -- $23.5 million, up $2.6 million from the prior year period, ...

Entered into broad strategic collaboration with Eli Lilly and Company ('Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment ...

Operator: Ladies and gentlemen, thank you for joining us today. And third quarter 2025 results conference call. At this time, ...